Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

y be necessary due to hepatotoxicity, other nonhematologic adverse events, or hematologic adverse events. Therapy with Gleevec was discontinued for adverse events in 5% of patients at both dose levels studied

Patients with severe hepatic impairment should be treated at a starting dose of 300 mg/day and should be closely monitored

Gleevec is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Dosage of Gleevec should increase by at least 50%, and clinical response should be carefully monitored, in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may significantly interact with Gleevec include acetaminophen, warfarin, erythromycin, and phenytoin. (Please see full Prescribing Information for other potential drug interactions)

For daily dosing of 800 mg and above, dosing should be accomplished using the 400 mg tablet to reduce exposure to iron

Use of Gleevec tablets is contraindicated in patients with hypersensitivity to imatinib or to any other component of Gleevec tablets

Women of childbearing potential should be advised to avoid becoming pregnant while taking Gleevec tablets and should be advised to avoid breast- feeding while taking Gleevec tablets because of the potential for serious adverse reactions in nursing infants

Common Side Effects of Gleevec Tablets

The majority of patients who received Gleevec in the GIST study experienced adverse events at some time. Most adverse events were mild to moderate in severity. The most frequently reported adverse events (400 mg/day; 600 mg/day) (all Grades) were superficial edema (81%; 77%), nausea (63%; 74%), muscle cramps (47%; 58%), diarrhea (59%; 70%), fatigue (48%; 53%), abdominal pain (40%; 37%), rash and related terms (38%; 53%), vomiting (38%; 35%) musculoskeletal pain (37%; 30%), and hemorrhage (26%; 34%)**

Supportive care may help management of some mild
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:4/17/2015)... 17, 2015 CVS Health Corporation (NYSE: ... Friday, May 1, 2015, at 8:30 a.m. (EDT) with ... results. An audio webcast of the conference ... portion of the CVS Health website for all interested ... This webcast will be archived and available on the ...
(Date:4/17/2015)...  Trovagene, Inc., (NASDAQ:  TROV) a developer of ... presented at the 2015 European Lung Cancer Conference ... ℠ (PCM) platform outperformed tissue biopsy for ... mutations in metastatic lung cancer patients. The ... in Urinary Circulating Tumor DNA from Metastatic Non-Small ...
(Date:4/17/2015)... 17, 2015  Over the next five years, the marijuana ... with ArcView predicting that 14 more states will legalize recreational ... U.S. market for legal cannabis grew 74 percent in 2014 ... project the market could grow more than fourfold to $11 ... their stance on marijuana. Cannabiz Mobile Inc. (OTCBB: ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... RESTON, Va., June 1, 2011 Mirixa Corporation is ... signed a licensing agreement for MirixaEdge(SM), a clinical application ... including Medication Therapy Management (MTM). Family Physicians ... with One Source Pharmacy and selected it as FPG,s ...
... Reportlinker.com announces that a new market ... Global Intravenous (IV) Iron ... This report analyzes the ... in US$ Million. The report provides separate ...
Cached Medicine Technology:MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 2MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 3Global Intravenous (IV) Iron Drugs Industry 2Global Intravenous (IV) Iron Drugs Industry 3Global Intravenous (IV) Iron Drugs Industry 4Global Intravenous (IV) Iron Drugs Industry 5Global Intravenous (IV) Iron Drugs Industry 6Global Intravenous (IV) Iron Drugs Industry 7
(Date:4/17/2015)... 17, 2015 ERGO-Pedic Products, LLC, which ... two new products to help a broader range of ... relief are the second most common visitors to doctors. ... designed specifically to help relieve sitting pain. Then, only ... thousands of happy customers later, we began getting questions ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital ... Carrollwood were all selected as Top Workplaces in Tampa ... County, is ranked number one for large businesses according ... conducted in partnership with an independent research firm. Florida ... that opened in October of 2012 with a vision ...
(Date:4/17/2015)... Washington, D.C. (PRWEB) April 17, 2015 ... today issued the following statement: “On Wednesday April 15th, ... bodies and adopted a resolution recognizing the Armenian Genocide, ... the memory of the one-and-a-half million innocent Armenian victims ... of Christians (IDC) extols the EU for this timely ...
(Date:4/17/2015)... April 17, 2015 Enthusiasts of gourmet cuisine ... Saturday, April 25, 2015. The event will be held in ... Food (201 Monroe Ave NW, Grand Rapids, MI 49503) and ... West Michigan area. Patrons are encouraged to savor the food ... fun. , This year’s event will feature seven chefs, including:, ...
(Date:4/17/2015)... Fla. (PRWEB) April 17, 2015 Most ... of dental restoration units are made overseas by foreign ... Additionally, domestic labs remain unregulated in more than 40 ... The National Association of Dental Laboratories has ... to raise awareness among patients about the consequences that ...
Breaking Medicine News(10 mins):Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:National Association Urges Transparency in Dental Industry 2
... patient in West Bengal was first refused treatment by ... till a human rights group intervened to unshackle him, ... hospital superintendent by the Association for the Protection of ... Bagda in North 24 Parganas district freed., ,Debnath ...
... Watch had explored the physiology// of hot flashes experienced by ... flashes are well known to most menopausal women—and to many ... tend to come on suddenly and last from one to ... to a feeling of being on fire. , ,Although ...
... for a new drug to treat women with //low sexual desire. ... to be done on the Intrinsa patch made by Procter & ... drug may induce, the Los Angeles Times reported. , ... healthy sexual appetites to women struggling with low desire., ...
... with higher air pollution levels may have an increased chance ... cleaner surroundings., ,The research done by scientists from Loma ... of the journal Environmental Health Perspectives. Their research findings suggest ... in women is more if they happen to live in ...
... Adyar Cancer Institute director Dr.V. Shanta is among this year's ... the prize for public service and her "untiring leadership of ... for the study and treatment of cancer// in India." ... also won a number of national and international awards. On ...
... may have increased risk of death if they choose ... University School of Medicine have found that in people// ... hemodialysis increases their risk of dying by 50 percent. ... journal Annals of Internal Medicine online Aug. 1, are ...
Cached Medicine News:Health News:Insight for Hot Flashes In Postmenopausal Women 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Air Pollution Increases Risk For Heart Disease In Women 2Health News:Magsaysay Award for Dr.Shanta from Chennai Cancer Institute 2Health News:Choice Of Treatment Increases Risk Of Death In Kidney Disease 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: